{"id":"NCT05163496","sponsor":"University of Washington","briefTitle":"Frontline Clinician Psilocybin Study","officialTitle":"A Randomized, Placebo-controlled Trial of Psychedelic-assisted Psychotherapy With Single Dose Psilocybin for Frontline Clinicians Experiencing COVID-related Symptoms of Depression and Burnout","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-03-03","primaryCompletion":"2023-12-30","completion":"2024-06-30","firstPosted":"2021-12-20","resultsPosted":"2025-03-18","lastUpdate":"2025-03-18"},"enrollment":30,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Burnout, Caregiver","Burnout, Professional","COVID-19","Depression","Post Traumatic Stress Disorder","Moral Injury"],"interventions":[{"type":"DRUG","name":"Psilocybin (Usona Institute)","otherNames":["Psychedelic-assisted psychotherapy (PAP)"]},{"type":"DRUG","name":"Active placebo","otherNames":["PAP with placebo"]}],"arms":[{"label":"Psilocybin arm","type":"EXPERIMENTAL"},{"label":"Placebo","type":"ACTIVE_COMPARATOR"}],"summary":"This study aims to investigate the effects of a single dose of psilocybin, delivered in the contextof pre- and post-dose psychotherapy, on symptoms of depression and burnout suffered by healthcare clinicians as a result of frontline work in the COVID pandemic.","primaryOutcome":{"measure":"Montgomery-Asberg Depression Rating Scale","timeFrame":"4-weeks post psilocybin-assisted psychotherapy","effectByArm":[{"arm":"Psilocybin Arm","deltaMin":21.33,"sd":7.84},{"arm":"Placebo","deltaMin":9.33,"sd":7.32}],"pValues":[{"comp":"OG000 vs OG001","p":"<.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["39636638"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":15},"commonTop":[]}}